The safety and efficacy of full‐ versus reduced‐dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended‐Duration Betrixaban (APEX) trial
Sign Up to like & getrecommendations! Published in 2017 at "American Heart Journal"
DOI: 10.1016/j.ahj.2016.12.004
Abstract: Background The APEX trial assessed the safety and efficacy of extended‐duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80‐mg betrixaban dose was halved to 40 mg among… read more here.
Keywords: safety; extended duration; apex trial; efficacy ... See more keywords